January 16, 2008

SpeculatingStocks.com Stock Pick: Replidyne, Inc. (RDYN)

Stock Price: $2.45

Replidyne, Inc. is a biopharmaceutical company focusing on discovering, developing, in-licensing, and commercializing anti-infective products. Its products include Faropenem Medoxomil, an oral antibiotic; and REP8839, an anti-infective product, which is in Phase I clinical development for the treatment of skin and wound infections comprising methicillin resistant Staphylococcus aureus.

RDYN recently provided a strategic update including restructuring and pipeline prioritization in line with strategic priorities. This came as RDYN dropped from the $6.00 level to as low as $2.05.

RDYN has just begun to turn around with a strong reversal after a three day bottom. RDYN is currently trading at a market cap of only $66.17 million with revenue in 2006 of $15.98 million.

As of November 30, 2007, Replidyne had cash assets of approximately $93 million. The company believes it has internal cash resources to support operations for at least the next two fiscal years. RDYN has a strong balance sheet with no long term debt and assets exceeding liabilities by over 12 to 1.